Corcept (CORT) Up 9.2% Since Last Earnings Report: Can It Continue?
Corcept (CORT) reported earnings 30 days ago. What's next for the stock?
Will Korlym Continue to Drive Corcept's Top Line in 2026?
CORT leans on rising Korlym sales while awaiting key relacorilant FDA decisions that could broaden its growth path in 2026.
Corcept Q3 Earnings & Revenues Lag Estimates, '25 View Cut, Stock Down
CORT's third-quarter earnings and sales miss estimate. The company cuts guidance despite a 14% year-over-year rise in revenues.
Corcept Therapeutics Incorporated (CORT) Q3 2025 Earnings Call Transcript
Corcept Therapeutics Incorporated ( CORT ) Q3 2025 Earnings Call November 4, 2025 5:00 PM EST Company Participants Atabak Mokari - CFO & Treasurer Gary Robb - Chief Business Officer & Secretary Sean Maduck - President of Endocrinology Joseph K. Belanoff - Co-Founder, President, CEO & Director William Guyer - Chief Development Officer Conference Call Participants Edward Nash - Canaccord Genuity Corp., Research Division David Amsellem - Piper Sandler & Co., Research Division Asim Rana - Truist Securities, Inc., Research Division Swayampakula Ramakanth - H.C.
Corcept Therapeutics (CORT) Q3 Earnings and Revenues Miss Estimates
Corcept Therapeutics (CORT) came out with quarterly earnings of $0.16 per share, missing the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.41 per share a year ago.
Analysts Estimate Corcept Therapeutics (CORT) to Report a Decline in Earnings: What to Look Out for
Corcept (CORT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CORT Files MAA for Relacorilant in Platinum-Resistant Ovarian Cancer
Corcept files a marketing application with the EMA for relacorilant in platinum-resistant ovarian cancer after studies show survival gains.
Can Relacorilant Drive Corcept's Long-Term Growth Beyond Korlym?
Corcept expects relacorilant to ease sole reliance on Korlym for revenues. Relacorilant is under FDA review for Cushing's syndrome and ovarian cancer.
Corcept Primed For An Upside EPS Surprise
My September quarter EPS forecast of $0.29 for Corcept could meaningfully beat analyst projections of $0.17. Approval of the company's Relacorilant medication by the FDA will essentially resolve any generic threat of its current medication, Korlym. Corcept's patient base has increased from about 10,000 to over 1 million hard-to-treat diabetics.
FDA Accepts Corcept's NDA for Relacorilant in Ovarian Cancer
CORT's NDA for relacorilant in platinum-resistant ovarian cancer gains FDA acceptance, with a decision expected by July 2026.
Corcept Shares Rise 39.6% in YTD: How Should You Play the Stock?
CORT's stock is up 39.6% year to date as relacorilant nears FDA approval for Cushing's syndrome and expands into cancer studies.
Corcept's Q2 Demand Grows 60%, Penetrating Large Type 2 Diabetes Market Early
Corcept's Q2 2025 results were impacted by specialty pharmacy bottlenecks and discounting, masking robust underlying 60% growth in demand for its therapies. Revenue guidance was trimmed on fulfillment issues, but true demand and revenue growth may be accelerating as a large new market is penetrated, pharmacy capacity expands, and new products launch. Physician adoption of Corcept's therapies is ramping earlier than we expected, supporting a long-term outlook for 30-50% annual revenue growth and significant market expansion.
